Home › Funds › DODGE & COX › GSK
DODGE & COX position in GSK
GSK PLC · Health Care
DODGE & COX reported holding 43,183,117 shares of GSK (GSK PLC) in its Q3 2026 13F filing — a position valued at US$2.08B, representing 1.12% of its reported portfolio and ranking #33 among its reported holdings. DODGE & COX has disclosed GSK holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How DODGE & COX's GSK position evolved
DODGE & COX first disclosed a stake in GSK in Q3 2023 at 69,281,183 shares (US$2.51B). The position peaked in Q3 2025 at 78,403,734 shares, worth US$3.38B. Across 13 filings, DODGE & COX increased the stake 2 time(s), trimmed it 5 time(s) and left it unchanged 5 time(s). The most recent filing (Q3 2026) shows 43,183,117 shares valued at US$2.08B — a reduction of -5,014,397 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 69.28M | $2.51B | New |
| Q4 2023 | 69.03M | $2.56B | Hold |
| Q1 2024 | 68.86M | $2.95B | Hold |
| Q2 2024 | 68.34M | $2.63B | Reduce |
| Q3 2024 | 68.09M | $2.78B | Hold |
| Q4 2024 | 68.44M | $2.31B | Add |
| Q1 2025 | 78.65M | $3.05B | Add |
| Q2 2025 | 78.76M | $3.02B | Hold |
| Q3 2025 | 78.40M | $3.38B | Hold |
| Q4 2025 | 68.52M | $3.36B | Reduce |
| Q1 2026 | 58.66M | $3.24B | Reduce |
| Q2 2026 | 48.20M | $2.53B | Reduce |
| Q3 2026 | 43.18M | $2.08B | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About GSK and 13F data
GSK (GSK PLC) is a Health Care company. 19 other funds we track also report a position in GSK — the largest reported positions include Dodge & Cox (US$2.53B), PRIMECAP MANAGEMENT CO/CA/ (US$1.21B), JTC Employer Solutions Trustee Ltd (US$389.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding GSK
- Dodge & Cox 48.20M sh · $2.53B · Q2 2026
- PRIMECAP MANAGEMENT CO/CA/ 25.19M sh · $1.21B · Q3 2026
- JTC Employer Solutions Trustee Ltd 8.08M sh · $389.17M · Q3 2026
- Mondrian Investment Partners LTD 4.97M sh · $239.21M · Q3 2026
- Grantham, Mayo, Van Otterloo & Co. LLC 3.92M sh · $188.73M · Q3 2026
- EQUITY INVESTMENT CORP 3.56M sh · $171.52M · Q3 2026
More on DODGE & COX
FAQ
How long has DODGE & COX held GSK?
DODGE & COX has disclosed GSK holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is DODGE & COX's current position in GSK?
As of Q3 2026, DODGE & COX holds 43.18M shares of GSK (GSK PLC), valued at $2.08B, representing 1.12% of its reported portfolio and ranking #33.
Has DODGE & COX been buying or selling GSK?
In the latest 13F filing (Q3 2026), DODGE & COX reduced its position in GSK. The position peaked in Q3 2025 at 78.40M shares.
Which other funds hold GSK?
Other major institutional holders of GSK include Dodge & Cox, PRIMECAP MANAGEMENT CO/CA/, JTC Employer Solutions Trustee Ltd, among 19 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.